

PHARMACEUTICAL 2022

Evolus Inc. Rank 326 of 466









PHARMACEUTICAL 2022

## Evolus Inc. Rank 326 of 466



The relative strengths and weaknesses of Evolus Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Evolus Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 42% points. The greatest weakness of Evolus Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 103% points.

The company's Economic Capital Ratio, given in the ranking table, is 43%, being 35% points below the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	178,799
Cost of Goods Sold	43,534
Intangible Assets	71,833
Liabilities, Current	57,663
Liabilities, Non-Current	2,256
Other Assets	5,480
Other Compr. Net Income	0
Other Expenses	-13,546
Other Liabilities	115,688
Other Net Income	-2,363
Other Revenues	99,673
Property and Equipment	1,371
Research and Development	2,064
Selling, General and Administrative Expense	112,068

Output Variable	Value in 1000 USD
Assets	257,483
Liabilities	175,607
Expenses	144,120
Revenues	99,673
Stockholders Equity	81,876
Net Income	-46,810
Comprehensive Net Income	-46,810
Economic Capital Ratio	43%

